Nicole A Groth1, Neil J Stone2, Catherine P Benziger3. 1. Essentia Institute of Rural Health, Duluth, Minnesota, USA. 2. Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. 3. Essentia Health Heart and Vascular Center, Duluth, Minnesota, USA.
Abstract
BACKGROUND: Patients with phenotypic severe hypercholesterolemia (SH), low-density lipoprotein-cholesterol (LDL-c) ≥ 190 mg/dl, atherosclerotic cardiovascular disease (ASCVD) or adults 40-75 years with diabetes with risk factors or 10-year ASCVD risk ≥20% benefit from maximally tolerated statin therapy. Rural patients have decreased access to specialty care, potentially limiting appropriate treatment. HYPOTHESIS: Prior visit with cardiology will improve treatment of severe hypercholesterolemia. METHODS: We used an electronic medical record-based SH registry defined as ever having an LDL-c ≥ 190 mg/dl since January 1, 2000 (n = 18 072). We excluded 3205 (17.7%) patients not alive or age 20-75 years. Patients defined as not seen by cardiology if they had no visit within the past 3 years (2017-2019). RESULTS: We included 14 867 patients (82.3%; mean age 59.7 ± 10.3 years; 58.7% female). Most patients were not seen by cardiology (n = 13 072; 72.3%). After adjusting for age, sex, CVD, hypertension, diabetes and obesity, patients seen by cardiology were more likely to have any lipid-lowering medication (OR = 1.46, 95% CI: 1.29-1.65), high-intensity statin (OR = 1.81, 95% CI: 1.61-2.03), or proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor (OR = 5.96, 95% CI: 3.34-10.65) compared to those not seen by cardiology. Mean recent LDL-c was lower in patients seen by cardiology (126.8 ± 51.6 mg/dl vs. 152.4 ± 50.2 mg/dl, respectively; p < .001). CONCLUSION: In our predominantly rural population, a visit with cardiology improved the likelihood to be prescribed any statin, a high-intensity statin, or PCSK9 inhibitor. This more appropriately addressed their high life-time risk of ASCVD. Access to specialty care could improve SH patient's outcomes.
BACKGROUND:Patients with phenotypic severe hypercholesterolemia (SH), low-density lipoprotein-cholesterol (LDL-c) ≥ 190 mg/dl, atherosclerotic cardiovascular disease (ASCVD) or adults 40-75 years with diabetes with risk factors or 10-year ASCVD risk ≥20% benefit from maximally tolerated statin therapy. Rural patients have decreased access to specialty care, potentially limiting appropriate treatment. HYPOTHESIS: Prior visit with cardiology will improve treatment of severe hypercholesterolemia. METHODS: We used an electronic medical record-based SH registry defined as ever having an LDL-c ≥ 190 mg/dl since January 1, 2000 (n = 18 072). We excluded 3205 (17.7%) patients not alive or age 20-75 years. Patients defined as not seen by cardiology if they had no visit within the past 3 years (2017-2019). RESULTS: We included 14 867 patients (82.3%; mean age 59.7 ± 10.3 years; 58.7% female). Most patients were not seen by cardiology (n = 13 072; 72.3%). After adjusting for age, sex, CVD, hypertension, diabetes and obesity, patients seen by cardiology were more likely to have any lipid-lowering medication (OR = 1.46, 95% CI: 1.29-1.65), high-intensity statin (OR = 1.81, 95% CI: 1.61-2.03), or proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor (OR = 5.96, 95% CI: 3.34-10.65) compared to those not seen by cardiology. Mean recent LDL-c was lower in patients seen by cardiology (126.8 ± 51.6 mg/dl vs. 152.4 ± 50.2 mg/dl, respectively; p < .001). CONCLUSION: In our predominantly rural population, a visit with cardiology improved the likelihood to be prescribed any statin, a high-intensity statin, or PCSK9 inhibitor. This more appropriately addressed their high life-time risk of ASCVD. Access to specialty care could improve SH patient's outcomes.
Authors: P Barton Duell; Samuel S Gidding; Rolf L Andersen; Thomas Knickelbine; Lars Anderson; Eugenia Gianos; Peter Shrader; Iris Kindt; Emily C O'Brien; Dervilla McCann; Linda C Hemphill; Catherine D Ahmed; Seth S Martin; John A Larry; Zahid S Ahmad; Iftikhar J Kullo; James A Underberg; John Guyton; Paul Thompson; Katherine Wilemon; Matthew T Roe; Daniel J Rader; Marina Cuchel; MacRae F Linton; Michael D Shapiro; Patrick M Moriarty; Joshua W Knowles Journal: Atherosclerosis Date: 2019-08-19 Impact factor: 5.162
Authors: Noura S Abul-Husn; Kandamurugu Manickam; Laney K Jones; Eric A Wright; Dustin N Hartzel; Claudia Gonzaga-Jauregui; Colm O'Dushlaine; Joseph B Leader; H Lester Kirchner; D'Andra M Lindbuchler; Marci L Barr; Monica A Giovanni; Marylyn D Ritchie; John D Overton; Jeffrey G Reid; Raghu P R Metpally; Amr H Wardeh; Ingrid B Borecki; George D Yancopoulos; Aris Baras; Alan R Shuldiner; Omri Gottesman; David H Ledbetter; David J Carey; Frederick E Dewey; Michael F Murray Journal: Science Date: 2016-12-23 Impact factor: 47.728
Authors: Hasan Rehman; Sarah T Ahmed; Julia Akeroyd; Dhruv Mahtta; Xiaoming Jia; Mahmoud Al Rifai; Khurram Nasir; Hani Jneid; Mirza U Khalid; Mahboob Alam; Peter P Toth; Salim S Virani Journal: Am J Cardiol Date: 2019-07-25 Impact factor: 2.778
Authors: Gregory G Schwartz; P Gabriel Steg; Michael Szarek; Deepak L Bhatt; Vera A Bittner; Rafael Diaz; Jay M Edelberg; Shaun G Goodman; Corinne Hanotin; Robert A Harrington; J Wouter Jukema; Guillaume Lecorps; Kenneth W Mahaffey; Angèle Moryusef; Robert Pordy; Kirby Quintero; Matthew T Roe; William J Sasiela; Jean-François Tamby; Pierluigi Tricoci; Harvey D White; Andreas M Zeiher Journal: N Engl J Med Date: 2018-11-07 Impact factor: 91.245
Authors: Abbey C Sidebottom; Marc C Vacquier; Joseph C Jensen; Steven M Bradley; Thomas Knickelbine; Craig Strauss; Michael D Miedema Journal: Clin Cardiol Date: 2020-02-27 Impact factor: 2.882
Authors: Fatima Rodriguez; Joshua W Knowles; David J Maron; Salim S Virani; Paul A Heidenreich Journal: Am J Cardiol Date: 2018-06-07 Impact factor: 2.778
Authors: Heiner K Berthold; Ioanna Gouni-Berthold; Michael Böhm; Wilhelm Krone; Kurt P Bestehorn Journal: Cardiovasc Diabetol Date: 2009-05-13 Impact factor: 9.951
Authors: Muin J Khoury; Scott Bowen; W David Dotson; Emily Drzymalla; Ridgely F Green; Robert Goldstein; Katherine Kolor; Leandris C Liburd; Laurence S Sperling; Rebecca Bunnell Journal: Genet Med Date: 2022-04-28 Impact factor: 8.864